Ro7663498

Phase 1

Roche

Ro7663498 is one of 37 therapeutic programs targeting Diabetic Retinopathy. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[2][1]

Indication

Diabetic RetinopathyRecruiting

Diabetic RetinopathyPhase 1

Recruiting

Competition

Competitive Landscape

99 competitors in Diabetic Retinopathy

#DrugCompanyPhaseTrials

Atacand

AstraZeneca

Phase 3

2 2

Bayer Aspirin

Bayer

Phase 3

1 3

Sandostatin

Novartis

Phase 3

—4

Circadin

NNeurim Pharmaceuticals Ltd.

Phase 3

2 5

Zocor

OOrganon and Co

Phase 3

2 6

Atacand

IIstituto Clinico Humanitas

Phase 3

1 7

Avastin

BBio-Thera Solutions

Phase 3

1 8

Octreotide Depot

Novartis

Phase 3

2 9

Pred Forte

Novartis

Phase 2

1 10

Alphagan

Novartis

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2027

Phase 1Recruiting

Diabetic Retinopathy

NCT07588100

Clinical

Trials by Indication[1]

Diabetic Retinopathy1 trial

A Multicenter, Non-Randomized, Open-Label, Multiple-Ascending-Dose Study to Investigate the Safety, Tolerability, and Pharmacokinetics of RO7663498 Following Intravitreal Administration in Participants With Diabetic Retinopathy

Recruiting· Roche logo

Roche·Phase 1·NCT07588100·30 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Ro7663498. U.S. National Library of Medicine, National Institutes of Health.
[2]
Open Targets Platform — Drug–disease associations for Ro7663498. EMBL-EBI & Wellcome Sanger Institute.
[3]
SEC EDGAR — Roche company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Highest Phase: Phase 1[1]
Company: Roche

Ro7663498

Status by Indication[2][1]

Competitive Landscape

Expected Milestones

Q4 2027

Trials by Indication[1]

Diabetic Retinopathy1 trial

References

Drug Info

Quick Facts

Related News